Scoop Independent News
By Evelyn Pringle
February 18, 2010
GlaxoSmithKline has paid out close to $1 billion to resolve lawsuits involving Paxil since the drug came on the market in 1992, according to a December 14, 2009 Bloomberg report. But the billion dollars does not cover the more than 600 Paxil birth defect cases currently pending in multi-litigation in Pennsylvania.
Glaxo has settled about 10 birth defect cases, according to Sean Tracey, a Houston attorney who represented the family of a child victim in the first jury trial that decided in favor of the plaintiff on October 13, 2009, Bloomberg reports. The settlements in those lawsuits averaged about $4 million, people familiar with the cases told the new service.
First Trial A Bust for Glaxo
The first trial, in the case of Kilker v Glaxo, ended with a jury in Philadelphia finding that Glaxo “negligently failed to warn” the doctor treating Lyam Kilker’s mother about Paxil’s risks and the drug was a “factual cause” of Lyam’s heart defects. The jury awarded the family $2.5 million in compensatory damages.
After the trial, juror Joe Mellon told Bloomberg that Glaxo did not conduct adequate studies on Paxil. “There were a couple of what I thought were safety signals and what the plaintiffs presented as safety signals that they should have maybe looked into further,” he said.
On October 14, 2009, the American Lawyer reported that the plaintiff’s lead attorney, Sean Tracey, had quizzed the jurors about what swayed their decision. “They said the fact that GSK never adequately studied their own drug was a big deal,” Tracey said. “The animal testing they did showed that they had a potential problem, and they didn’t follow up with adequate studies on animals or humans.”
Read entire article: http://www.scoop.co.nz/stories/HL1002/S00128.htm
News Feed
Related Posts
Tags: birth defects, Glaxo, GlaxoSmithKline, lawsuits, Paxil
This entry was posted on Wednesday, February 17th, 2010 at 7:02 pm and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Donate
[...] post: Paxil Birth Defect Litigation – 600 Cases Pending « CCHR International tags: bloomberg, cover-the-more, dollars-does, drug, drug-came, market, not-cover, [...]
Birth defects?! What else is new? 600 cases is not anything to worry about. I hope that they put a “Risk of birth defects during pregnancy”
label. Better yet get the crap off the shelf.
Seeing that we already happen to be discussing points regarding Paxil Birth Defect Litigation – 600 Cases Pending CCHR International, Corporate history firms are specialists at organizing information and finding the necessary stories to fill in the blanks your company officers might not even know. When the work of the researchers is complete, you’ll have a completed document or perhaps a commemorative book to distribute to employs or proudly display.